Clinical study of Hematide in chronic renal failure patients not on dialysis

Phase 3

• Conditions: Renal anemia

• Registration Number: JPRN-jRCT2080221073
• Lead Sponsor: Takeda Pharmaceutical Company Limited

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-04-15
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1) The subject has chronic renal failure and is not expected to start dialysis for at least 24 weeks after start of the study drug administration.
2) The subject has serum ferritin level of 100 ng/mL or more, or has transferrin saturation of 20% or more at the screening period.
3) The subject is capable of giving consent to participation in the study and understanding the informed consent form and other explanatory documents, and sings written consent.

Exclusion Criteria

1) The subject is known to be intolerant to ESA.
2) The subject is known to be intolerant to an iron preparation.
3) The subject has received red blood cell or whole blood transfusion within 12 weeks (84 days) prior to the study drug administration.
4) The subject has hemoglobinopathy (sickle cell disease, thalassemia, etc.).
5) The subject has any hemolytic disease or its past history.
etc.

Study & Design

• Study Type: Interventional
• Study Design: Not specified